Top Page
Shanghai Pharmaceuticals Holding Co
(OTC:2607)
Shanghai Pharmaceuticals Holding Co (2607) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Pharmaceuticals Holding Co Business Overview & Revenue Model
Shanghai Pharmaceuticals Holding Co Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 275.86B | 275.25B | 260.30B | 231.98B | 215.82B | 191.91B | Gross Profit |
| 29.77B | 30.63B | 30.93B | 30.49B | 28.54B | 27.44B | EBIT |
| 7.87B | 8.14B | 7.67B | 9.01B | 8.21B | 7.18B | EBITDA |
| 9.35B | 12.06B | 10.90B | 12.44B | 10.55B | 10.44B | Net Income Common Stockholders |
| 4.34B | 4.55B | 3.77B | 5.62B | 5.09B | 4.50B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 45.03B | 44.38B | 40.67B | 37.01B | 22.39B | 22.30B | Total Assets |
| 225.87B | 221.21B | 211.97B | 198.13B | 163.44B | 149.19B | Total Debt |
| 50.99B | 47.79B | 42.90B | 38.56B | 31.69B | 31.79B | Net Debt |
| 14.83B | 12.05B | 12.38B | 11.16B | 9.30B | 9.50B | Total Liabilities |
| 140.57B | 137.47B | 131.65B | 120.13B | 104.37B | 94.44B | Stockholders Equity |
| 73.01B | 71.68B | 68.52B | 67.06B | 49.36B | 45.35B |
| Cash Flow | Free Cash Flow | ||||
| 7.95B | 3.43B | 2.26B | 2.06B | 942.55M | 3.83B | Operating Cash Flow |
| 5.99B | 5.83B | 5.23B | 4.74B | 5.06B | 6.84B | Investing Cash Flow |
| 249.44M | 415.98M | -2.49B | ― | ― | ― | Financing Cash Flow |
| 4.38B | ― | 231.85M | 12.14B | 1.57B | ― |
Shanghai Pharmaceuticals Holding Co Technical Analysis
Shanghai Pharmaceuticals Holding Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$33.02B | 11.81 | 14.56% | 5.03% | -5.37% | 6.28% | |
71 Outperform | $58.32B | 7.63 | 9.19% | 5.60% | -3.94% | -23.48% | |
66 Neutral | HK$66.92B | 9.22 | 6.08% | 4.58% | 3.27% | 12.87% | |
66 Neutral | HK$81.02B | 42.70 | 6.14% | 1.33% | 7.63% | -24.23% | |
65 Neutral | $67.21B | 14.57 | 6.22% | 1.96% | -2.82% | 11.93% | |
62 Neutral | €32.92B | 9.06 | 3.05% | ― | ― | ||
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% |
Shanghai Pharmaceuticals Holding Co Corporate Events
Shanghai Pharmaceuticals Holding Co., Ltd. has released its first quarterly report for 2025, prepared in accordance with PRC Accounting Standards for Business Enterprises. The report, which remains unaudited, emphasizes the company’s commitment to transparency and accuracy in its financial disclosures, as affirmed by its board of directors and senior management.
Shanghai Pharmaceuticals Holding Co., Ltd. has completed the acquisition of a 10% equity interest in SHPL, making it a non-wholly owned subsidiary. This strategic move consolidates SHPL’s financial results into the company’s statements, potentially strengthening its market position and operational capabilities.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced its participation in the establishment of the Biomedical M&A Fund, alongside several partners, including Guotou Pioneer and Junshi Biosciences. The company has completed the necessary industrial and commercial registration procedures and filed with the Asset Management Association of China. This strategic move is expected to enhance Shanghai Pharmaceuticals’ capabilities in the biomedical sector, potentially impacting its operational growth and market positioning.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced a board meeting scheduled for April 28, 2025, to approve and publish the company’s first quarterly results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance and operational progress, potentially impacting its market positioning and stakeholder interests.
Shanghai Pharmaceuticals Holding Co., Ltd. announced a final cash dividend of RMB 2.9 per 10 shares for the financial year ending December 31, 2024. This announcement reflects the company’s ongoing commitment to returning value to its shareholders. The dividend will be subject to withholding tax, with specific rates depending on the shareholder’s residency and applicable tax treaties with China. This move is likely to impact the company’s financial operations and shareholder relations, reinforcing its position in the market.
Shanghai Pharmaceuticals Holding Co., Ltd. has established a Nomination Committee under its Board of Directors to enhance its corporate governance structure. The committee is tasked with analyzing and recommending candidates for directorship and senior management roles, ensuring a diverse and independent board composition that aligns with regulatory requirements.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced a change in the composition of its board committee. Ms. MAN Kwan has been appointed as a member of the Nomination Committee, effective from March 27, 2025. This appointment is part of the company’s ongoing efforts to strengthen its governance and enhance its strategic direction.
Shanghai Pharmaceuticals Holding Co., Ltd. announced the composition of its board of directors and their respective roles, effective from March 27, 2025. This announcement highlights the strategic leadership structure of the company, which is crucial for its governance and operational effectiveness, potentially impacting its market positioning and stakeholder confidence.
Shanghai Pharmaceuticals Holding Co., Ltd. announced its 2024 annual results, audited by Deloitte Touche Tohmatsu, reflecting the company’s adherence to China Accounting Standards. The results, reviewed by the Audit Committee, will be published on the Hong Kong Stock Exchange and the company’s website. This announcement underscores the company’s commitment to transparency and its strategic positioning in the pharmaceutical industry, potentially impacting stakeholders by reinforcing its market reputation.
Shanghai Pharmaceuticals Holding Co., Ltd. announced that its subsidiary, Shanghai Sine United Medicinal Herbs Co., Ltd., received an administrative penalty from the Shanghai Municipal Administration for Market Regulation for violating anti-monopoly laws. The penalty includes a fine and forfeiture of illegal income, but the financial impact on the parent company is limited due to the subsidiary’s small contribution to overall revenue. The company has taken steps to enhance compliance and prevent future monopolistic behavior, reflecting its commitment to fair market practices and sustainable development.
Shanghai Pharmaceuticals Holding Co., Ltd. held its first extraordinary general meeting of 2025, where key resolutions were passed, including amendments to the Articles of Association and the election of an independent director. The meeting was conducted in compliance with relevant legal and regulatory requirements, with a significant majority of shareholders voting in favor of the proposed changes. This development is expected to impact the company’s governance structure positively, potentially enhancing its strategic positioning and operational efficiency.
Shanghai Pharmaceuticals Holding Co., Ltd. announced the composition of its board of directors and their respective roles, effective March 13, 2025. This announcement highlights the company’s strategic focus on governance and leadership, potentially impacting its operational efficiency and stakeholder confidence.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced a board meeting scheduled for March 27, 2025, to approve the company’s annual results for the year ending December 31, 2024, and to consider the payment of a final dividend. This meeting is significant as it will determine the financial performance of the company and potentially impact its dividend distribution strategy, influencing stakeholders’ expectations and market positioning.
Shanghai Pharmaceuticals Holding Co., Ltd. issued a supplemental announcement regarding the upcoming extraordinary general meeting scheduled for March 13, 2025. The announcement clarifies the official English name of Dr. WAN Jun, a candidate for the independent non-executive director position, as Dr. WAN Jun MAN Kwan. The company assures stakeholders that the English version of the proxy form remains valid, and previous votes will be considered valid for the revised resolution.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced the details of its upcoming Extraordinary General Meeting, scheduled for March 13, 2025. The announcement indicates that the number of voting shares represented by shareholders planning to attend has not exceeded half of the total voting shares, which may impact the meeting’s proceedings and decisions.
Shanghai Pharmaceuticals Holding Co., Ltd. announced an update on its acquisition of a 10% equity interest in SHPL from HUTCHMED Investment. This transaction is part of a broader agreement where GP Health Service Capital will acquire a 35% stake in SHPL, with designated purchasers GP Fund and Zhibaihe Enterprise Management. The supplemental agreement amends the share transfer conditions and board composition, reflecting the strategic alignment of interests among the involved parties. This acquisition is expected to bolster Shanghai Pharmaceuticals’ influence in the pharmaceutical market, potentially enhancing its operational capabilities and market positioning.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced proposed amendments to its Articles of Association. The key changes include adjustments to the composition of the Board of Directors, ensuring compliance with relevant laws and regulations. These amendments are aimed at enhancing corporate governance and ensuring the Board’s composition is in line with the company’s strategic goals and regulatory requirements.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for March 13, 2025, to discuss and approve amendments to the company’s Articles of Association and the election of an independent director for its board. This meeting is pivotal for the company as it considers significant governance changes, potentially impacting its decision-making processes and future strategic direction.